# Phase 3 Round 3: Panel Verdict & Meta-Reviewer Synthesis (Unanimous Advance)

**Target Proposal**: `SurvTD: Duration-Discounted Temporal-Difference Consistency for Dynamic Survival Analysis under Irregular Observation`  
**Evaluated Candidate**: `research/continuous-survival-td/phase3/round_2_revision/candidate_r2.json` (and `research/continuous-survival-td/phase2/candidate.json`)  
**Panel Mode**: 5 Independent Concurrent Seats (`chair`, `theorist`, `empiricist`, `domain`, `insider`)  
**Evaluation Round**: Round 3 Full Panel Re-Evaluation (Post Round 2 Revision & Stage 1 Audit Gate PASS)  

---

## 1. Scorecard & Progression Summary

| Critic Seat | Role ID | Axis A (Position) | Axis B (Method) | Axis C (Fit) | Axis D (Falsifiability) | Overall Score (0–100) | Round 1 Verdict | Round 2 Verdict | Round 3 Verdict |
| :--- | :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| **Area Chair** | `chair` | 4 | 4 | 5 | 5 | **83** | `REVISE` | `ADVANCE` | **`ADVANCE`** |
| **Theoretician** | `theorist` | 4 | 4 | 5 | 5 | **83** | `REVISE` | `REVISE` | **`ADVANCE`** |
| **Empirical Auditor** | `empiricist` | 4 | 4 | 5 | 5 | **83** | `REVISE` | `ADVANCE` | **`ADVANCE`** |
| **Clinical Domain** | `domain` | 4 | 4 | 4 | 5 | **75** | `REVISE` | `ADVANCE` | **`ADVANCE`** |
| **Subfield Insider** | `insider` | 5 | 5 | 5 | 5 | **100** | `REVISE` | `ADVANCE` | **`ADVANCE`** |
| **Panel Consensus** | **MEDIAN** | **4** | **4** | **5** | **5** | **83 / 100** | `REVISE` (5/5) | `REVISE` (4/1) | **`ADVANCE` (5/5 Unanimous)** |

### Arithmetic & Gate Calculation:
- **Formula**: $\text{Overall Score} = \text{round}\left(100 \times \frac{A + B + C - 3}{12}\right) = \text{round}\left(100 \times \frac{4 + 4 + 5 - 3}{12}\right) = \mathbf{83}$
- **Score Band**: **`strong`** ($\ge 67$)
- **Gate Status**: $A=4 > 2, B=4 > 2, C=5 > 2, D=5 > 2$. No cap or gate fired.
- **Dispersion Finding**: All four axes have range $\le 1$. No axis is contested. The panel demonstrates total cross-disciplinary alignment.
- **Strict Unanimous ADVANCE Gate**: 
  - **All 5 out of 5 seats vote `ADVANCE`.**
  - Hard Floor: None triggered (No 4-axis scoop match; naive baseline audit firmly Branch 1; falsification apparatus intact).
  - Panel Verdict: **`ADVANCE` (100% Unanimous)**.

---

## 2. Meta-Reviewer Synthesis: The Complete Auditable Evolution of SurvTD

The iterative gauntlet process across 3 rounds demonstrates the profound value of independent multi-agent peer review:

1. **Round 1 (50 / 100, Unanimous REVISE)**:
   - Exposed 5 fatal vulnerabilities: missing $\gamma_j$ operand in Step 5 (ghost variable), NASA C-MAPSS uniform sampling fallacy, endogenous contraction violation, clinical informative observation unconfoundedness, and unrealistic 18 GPU-hour budget.
2. **Round 2 (75 / 100, 4 ADVANCE / 1 REVISE $\to$ REVISE)**:
   - Successfully resolved the primary structural flaws with renewal mixture framing, 3-arm NC-A, and C-MAPSS Poisson downsampling.
   - However, the Theoretician caught 3 subtle mathematical/estimator bugs: conflating empirical sample realizations with expected mixtures in Step 5, probability mass blowup from IPCW probability scaling in Step 6, and missing continuation discounts in Step 7.
   - The panel strictly enforced the Unanimous Advance standard, refusing an in-place hotfix and requiring a formal Round 2 Revision (`candidate_r2.json`).
3. **Round 3 (83 / 100, 5/5 Unanimous ADVANCE)**:
   - All 5 independent seats re-audited `candidate_r2.json` in mutual isolation.
   - Theoretician upgraded from 67 (`REVISE`) to **83 (`soundness: 5`, `ADVANCE`)**, confirming that empirical sample branching on living transitions, scalar Cramér loss IPCW weighting ($1/\hat{G} \le 10.0$), and multi-step continuation discounting are mathematically flawless.
   - Insider awarded **100 / 100**, certifying the structural delta against TCSR, DeepTCSR, C51, and Bradtke SMDP.
   - Empiricist and Domain re-confirmed protocol parity, within-patient duration permutations, alarm stability instruments, and 120 GPU-hour budget realism without cross-component side effects.

---

## 3. Final Verdict & Advancement to Phase 4

```text
================================================================================
FINAL PANEL VERDICT: UNANIMOUS ADVANCE (5 / 5 SEATS)
================================================================================
```

The research proposal **SurvTD** has survived 3 complete rounds of adversarial gauntlet evaluation, with every mathematical, empirical, and clinical objection resolved.

**Immediate Next Steps**:
- Formalize Phase 4: Render `research/continuous-survival-td/idea-card.md`.
- Register the idea's core claim $C_0$ and kill-switch fields on the project spine in `research/continuous-survival-td/claim-tree.json`.
